NASDAQ:SYNHSyneos Health Stock Price, Forecast & News

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SYNH stock has decreased by 1.8% and is now trading at $56.24. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syneos Health.

Syneos Health is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Syneos Health.

Syneos Health will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Syneos Health Inc (NASDAQ:SYNH) announced its quarterly earnings results on Thursday, April, 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.04. The business earned $1.16 billion during the quarter, compared to analysts' expectations of $1.14 billion. Syneos Health had a net margin of 4.13% and a return on equity of 10.33%. The company's quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.59 earnings per share. View Syneos Health's earnings history.

Syneos Health issued an update on its second quarter earnings guidance on Wednesday, June, 3rd. The company provided EPS guidance of $0.48-0.52 for the period, compared to the Thomson Reuters consensus estimate of $0.47. The company issued revenue guidance of $1-1.02 billion, compared to the consensus revenue estimate of $979.53 million.

11 brokerages have issued 1-year price targets for Syneos Health's stock. Their forecasts range from $42.00 to $82.00. On average, they anticipate Syneos Health's stock price to reach $60.45 in the next year. This suggests a possible upside of 7.5% from the stock's current price. View analysts' price targets for Syneos Health.

News stories about SYNH stock have trended negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syneos Health earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Syneos Health.

Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Square (SQ), AT&T (T), CVS Health (CVS), Gilead Sciences (GILD), UnitedHealth Group (UNH), Visa (V) and Delta Air Lines (DAL).

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health's stock is owned by many different institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.11%). Company insiders that own Syneos Health stock include Alistair Macdonald, H Lee Equity Fund Vi Thomas, Jason M Meggs, John M Dineen, Jonathan Olefson, Michelle Keefe, Paul Colvin and Robert Parks. View institutional ownership trends for Syneos Health.

SYNH stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, John M Dineen, Jonathan Olefson, and Paul Colvin. View insider buying and selling activity for Syneos Health.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYNH stock can currently be purchased for approximately $56.24.

Syneos Health has a market capitalization of $5.86 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.

The official website for Syneos Health is www.syneoshealth.com.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]